FDA Clears Updated Ezra Flash AI Software for MRI Scans
The updated AI-enabled software reportedly facilitates enhanced MRI imaging of the brain, abdomen, and pelvis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for updated artificial intelligence (AI) software that bolsters image quality on magnetic resonance imaging (MRI) scans.
Emphasizing noise reduction without sacrificing diagnostic integrity, the Ezra Flash AI software bolsters the quality of MRI scans of the brain, abdomen and pelvis, according to Ezra, the manufacturer of Ezra Flash AI.
In addition to enhanced neuroimaging, the newly FDA-cleared updates for the Ezra Flash AI software may provide visualization with abdominal and pelvic MRI scans, according to Ezra, the developer of the software. (Images courtesy of Ezra.)
The company maintained that the enhanced image quality obtained with Ezra Flash AI will provide greater clarity in MRI interpretation and precise analysis to facilitate a more timely diagnosis.
"The FDA clearance of Ezra Flash represents a significant advancement in making AI-powered cancer screening more accessible," said Daniel K. Sodickson, M.D., Ph.D, the chief scientific advisor at Ezra and chief of innovation in the Department of Radiology at the New York University Grossman School of Medicine. "This technology enables faster, more accurate early cancer detection, ultimately giving patients and their doctors clearer insights for making informed healthcare decisions."
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which will be unveiled at the American College of Cardiology (ACC) conference.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
